NeuroinflammationPre-clinical
CNS Injury
Aviceda’s focus is to modulate the innate immune system with glyco-mimetics. Inflammatory cells, including macrophages, microglia and complement have emerged as central effectors for multiple neurological indications. We aim to use our technology to cross the BBB (blood brain barrier) to expand the potential applications of therapeutics for a variety of neurodegenerative and nerve injury indications.
